18F-fluorobenzoate-labeled cystine knot peptides for PET imaging of integrin αvβ6

Journal of Nuclear Medicine

Volumn 54, Issue 7, 2013, Pages 1101-1105

  Hackel, Benjamin J ^a   Kimura, Richard H ^a   Miao, Zheng ^a   Liu, Hongguang ^a   Sathirachinda, Ataya ^a   Cheng, Zhen ^a   Chin, Frederick T ^a   Gambhir, Sanjiv S ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford University   (United States)

Author keywords

Cystine knot; Integrin v 6; Positron emission tomography

Indexed keywords

ALPHAVBETA6 INTEGRIN; CYSTINE KNOT PEPTIDE; FLUOROBENZOATE F 18; PEPTIDE; PROTEIN R01; PROTEIN S02; RADIOISOTOPE; UNCLASSIFIED DRUG; 4 FLUOROBENZOIC ACID; 4-FLUOROBENZOIC ACID; BENZOIC ACID DERIVATIVE; DIAGNOSTIC AGENT; INTEGRIN; RADIOPHARMACEUTICAL AGENT; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOENGINEERING; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PURITY; EX VIVO STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; ISOTOPE LABELING; KIDNEY PARENCHYMA; MOLECULAR DIAGNOSIS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN STABILITY; TISSUE SPECIFICITY; TUMOR XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; CYSTINE KNOT; INTEGRIN ΑVΒ6; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; NUDE MOUSE; PANCREAS TUMOR; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

CYSTINE KNOT; INTEGRIN ΑVΒ6; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; ANTIGENS, NEOPLASM; BENZOATES; CELL LINE, TUMOR; FEMALE; INTEGRINS; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; MOLECULAR IMAGING; ORGAN SPECIFICITY; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84879972628     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.110759     Document Type: Article

References (25)

1. Breuss JM, Gallo J, DeLisser HM, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 1995;108:2241-2251.
2. Sipos B, Hahn D, Carceller A, et al. Immunohistochemical screening for beta6- integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology. 2004;45:226-236.
3. Maubant S, Cruet-Hennequart S, Dutoit S, et al. Expression of alpha V-associated integrin beta subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens. J Mol Histol. 2005;36:119-129.
4. Orimoto AM, Neto CF, Pimentel ERA, et al. High numbers of human skin cancers express MMP2 and several integrin genes. J Cutan Pathol. 2008;35:285-291.
5. Bates RC, Bellovin DI, Brown C, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 2005;115:339-347.
6. Elayadi AN, Samli KN, Prudkin L, et al. A peptide selected by biopanning identifies the integrin avb6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 2007;67:5889-5895.
7. Hazelbag S, Kenter GG, Gorter A, et al. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol. 2007;212:316-324.
8. Zhang Z-Y, Xu K-S, Wang J-S, et al. Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma. Clin Oncol (R Coll Radiol). 2008;20:61-66.
9. Yang G-Y, Xu K-S, Pan Z-Q, et al. Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci. 2008;99:879-887.
10. Hausner SH, DiCara D, Marik J, Marshall JF, Sutcliffe JL. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin avb6 expression with positron emission tomography. Cancer Res. 2007;67:7833-7840.
11. Hausner SH, Abbey CK, Bold RJ, et al. Targeted in vivo imaging of integrin avb6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res. 2009;69:5843-5850.
12. Nothelfer E-M, Zitzmann-Kolbe S, Garcia-Boy R, et al. Identification and characterization of a peptide with affinity to head and neck cancer. J Nucl Med. 2009;50:426-434.
13. Kimura RH, Teed R, Hackel BJ, et al. Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin Cancer Res. 2012;18:839-849.
14. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011.
15. Chen X, Park R, Shahinian AH, et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179-189.
16. Cai W, Olafsen T, Zhang X, et al. PET imaging of colorectal cancer in xenograftbearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med. 2007;48:304-310.
17. Lipovsek D, Lippow SM, Hackel BJ, et al. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J Mol Biol. 2007;368:1024-1041.
18. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-3108.
19. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
20. Miao Z, Ren G, Liu H, Jiang L, Cheng Z. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. Bioconjug Chem. 2010;21:947-954.
21. Cheng Z, Jesus OP, Kramer DJ, et al. 64Cu-Labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol. 2010;12:316-324.
22. Cheng Z, De Jesus OP, Namavari M, et al. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med. 2008;49:804-813.
23. Ahlgren S, Orlova A, Rosik D, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem. 2008;19:235-243.
24. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and 18Flabeled affibody molecules. J Nucl Med. 2009;50:1131-1139.
25. Moore SJ, Leung CL, Cochran Jr. Knottins: disulfide-bonded therapeutic and diagnostic peptides. Drug Discov Today Technol. 2012;9:e3-e11.